X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Capsida will provide GMP manufacturing of KateTx's gene therapies as the medicines advance through preclinical and clinical development for muscle and heart disease programs.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Capsida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 03, 2023
Details:
The proceeds will support the advancement of KateTx’s next generation AAV-based gene therapies for muscle and heart disease programs, including myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, which are the leading causes of adult-onset muscular dystrophy.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Westlake Village BioPartners
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 08, 2023
Details:
Astellas will receive license to develop, manufacture and commercialize KT430, a preclinical next-generation investigational AAV-based gene therapy that delivers a functional copy of the MTM1 gene via a novel MyoAAV capsid to treat X-linked myotubular myopathy.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: KT430
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 08, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
